+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Colitis - Pipeline Review, H2 2020

  • ID: 5137300
  • Drug Pipelines
  • July 2020
  • Region: Global
  • 116 pages
  • Global Markets Direct

FEATURED COMPANIES

  • 9 Meters Biopharma Inc
  • enGene Inc
  • Himuka AM Pharma Corp
  • MAKScientific LLC
  • Serpinx BV
  • TPCera Ltd
  • MORE
Colitis - Pipeline Review, H2 2020

Summary

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Colitis - Pipeline Review, H2 2020, provides an overview of the Colitis (Gastrointestinal) pipeline landscape.

Colitis is swelling (inflammation) of the large intestine (colon). Colitis can have many different causes, including infections, including those caused by a virus, parasite, and food poisoning due to bacteria, inflammatory disorders (ulcerative colitis and Crohn's disease), lack of blood flow (ischemic colitis), past radiation to the large bowel). Symptoms can include abdominal pain, bloating, bloody stools, chills, dehydration, diarrhea and fever. Treatment includes non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids.

Report Highlights

The publisher's Pharmaceutical and Healthcare latest pipeline guide Colitis - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Colitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Colitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Colitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, IND/CTA Filed and Preclinical stages are 1, 1, 1 and 25 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 7 molecules, respectively.

Colitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Colitis (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Colitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Colitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Colitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Colitis (Gastrointestinal)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Colitis (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Colitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • 9 Meters Biopharma Inc
  • enGene Inc
  • Himuka AM Pharma Corp
  • MAKScientific LLC
  • Serpinx BV
  • TPCera Ltd
  • MORE
  • Introduction
  • Colitis - Overview
  • Colitis - Therapeutics Development
  • Colitis - Therapeutics Assessment
  • Colitis - Companies Involved in Therapeutics Development
  • Colitis - Drug Profiles
  • Colitis - Dormant Projects
  • Colitis - Discontinued Products
  • Colitis - Product Development Milestones
  • Appendix
List of Tables
  • Number of Products under Development for Colitis, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products under Development by Companies, H2 2020 (Contd..1), H2 2020
  • Number of Products under Development by Universities/Institutes, H2 2020
  • Products under Development by Companies, H2 2020
  • Products under Development by Companies, H2 2020 (Contd..1), H2 2020
  • Products under Development by Universities/Institutes, H2 2020
  • Number of Products by Stage and Target, H2 2020
  • Number of Products by Stage and Mechanism of Action, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Colitis - Pipeline by 9 Meters Biopharma Inc, H2 2020
  • Colitis - Pipeline by Alfasigma SpA, H2 2020
  • Colitis - Pipeline by Apollo Endosurgery Inc, H2 2020
  • Colitis - Pipeline by Citryll BV, H2 2020
  • Colitis - Pipeline by enGene Inc, H2 2020
  • Colitis - Pipeline by ExCellThera Inc, H2 2020
  • Colitis - Pipeline by First Wave Bio Inc, H2 2020
  • Colitis - Pipeline by GeneFrontier Corp, H2 2020
  • Colitis - Pipeline by Himuka AM Pharma Corp, H2 2020
  • Colitis - Pipeline by Immodulon Therapeutics Ltd, H2 2020
  • Colitis - Pipeline by Immuron Ltd, H2 2020
  • Colitis - Pipeline by Inflazome Ltd, H2 2020
  • Colitis - Pipeline by Jubilant Therapeutics Inc, H2 2020
  • Colitis - Pipeline by MAKScientific LLC, H2 2020
  • Colitis - Pipeline by Nippon Kayaku Co Ltd, H2 2020
  • Colitis - Pipeline by Protagonist Therapeutics Inc, H2 2020
  • Colitis - Pipeline by Riptide Bioscience Inc, H2 2020
  • Colitis - Pipeline by Scholar Rock Inc, H2 2020
  • Colitis - Pipeline by Serpinx BV, H2 2020
  • Colitis - Pipeline by Soligenix Inc, H2 2020
  • Colitis - Pipeline by Symbiotix Biotherapies Inc, H2 2020
  • Colitis - Pipeline by Synthetic Biologics Inc, H2 2020
  • Colitis - Pipeline by TaiRx Inc, H2 2020
  • Colitis - Pipeline by TPCera Ltd, H2 2020
  • Colitis - Pipeline by Vascular Biogenics Ltd, H2 2020
  • Colitis - Pipeline by Vedanta Biosciences Inc, H2 2020
  • Colitis - Pipeline by Vitality Biopharma Inc, H2 2020
  • Colitis - Dormant Projects, H2 2020
  • Colitis - Dormant Projects, H2 2020 (Contd..1), H2 2020
  • Colitis - Dormant Projects, H2 2020 (Contd..2), H2 2020
  • Colitis - Discontinued Products, H2 2020
List of Figures
  • Number of Products under Development for Colitis, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products by Top 10 Targets, H2 2020
  • Number of Products by Stage and Top 10 Targets, H2 2020
  • Number of Products by Top 10 Mechanism of Actions, H2 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
  • Number of Products by Routes of Administration, H2 2020
  • Number of Products by Stage and Routes of Administration, H2 2020
  • Number of Products by Top 10 Molecule Types, H2 2020
  • Number of Products by Stage and Top 10 Molecule Types, H2 2020
Note: Product cover images may vary from those shown
  • 9 Meters Biopharma Inc
  • Alfasigma SpA
  • Apollo Endosurgery Inc
  • Citryll BV
  • enGene Inc
  • ExCellThera Inc
  • First Wave Bio Inc
  • GeneFrontier Corp
  • Himuka AM Pharma Corp
  • Immodulon Therapeutics Ltd
  • Immuron Ltd
  • Inflazome Ltd
  • Jubilant Therapeutics Inc
  • MAKScientific LLC
  • Nippon Kayaku Co Ltd
  • Protagonist Therapeutics Inc
  • Riptide Bioscience Inc
  • Scholar Rock Inc
  • Serpinx BV
  • Soligenix Inc
  • Symbiotix Biotherapies Inc
  • Synthetic Biologics Inc
  • TaiRx Inc
  • TPCera Ltd
  • Vascular Biogenics Ltd
  • Vedanta Biosciences Inc
  • Vitality Biopharma Inc
Note: Product cover images may vary from those shown
Adroll
adroll